🇺🇸 FDA
Patent

US 10920223

Serpina1 iRNA compositions and methods of use thereof

granted A61KA61K31/712A61K31/713

Quick answer

US patent 10920223 (Serpina1 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K31/712, A61K31/713, A61P, A61P1/00